A Novel Case Study of the Use of Real-World Evidence to Support the Registration of an Osteoporosis Product in China

On June 23, 2020, Prolia(®) (denosumab) was approved by the National Medical Products Administration (NMPA) in the People’s Republic of China as the first monoclonal antibody for the treatment of postmenopausal women with osteoporosis at high risk of fractures. Its brand name in Chinese is 普罗力, a tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Storm, Neal E., Chang, Wen, Lin, Tzu-Chieh, Lange, Jeff L., Bradbury, Brian, Critchlow, Cathy W., Galson, Steven K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688380/
https://www.ncbi.nlm.nih.gov/pubmed/34633649
http://dx.doi.org/10.1007/s43441-021-00342-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688380/
https://www.ncbi.nlm.nih.gov/pubmed/34633649
http://dx.doi.org/10.1007/s43441-021-00342-4

Ejemplares similares